Early definite stent thrombosis with everolimus-eluting stents

Ryo Naito1, Katsumi Miyauchi1, Hirokazu Konishi1

  • 1Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine Tokyo, Japan.

Clinical Case Reports
|October 29, 2015
PubMed

Insights

Stent thrombosis (ST) is a severe complication after coronary intervention. This case highlights how limited blood flow and antiplatelet resistance can cause ST, even with advanced stents.

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Biomedical Engineering

Background:

  • Percutaneous coronary intervention (PCI) is a common procedure for coronary artery disease.
  • Stent thrombosis (ST) is a rare but serious complication following PCI.
  • Everolimus-eluting stents (EES) are designed to minimize ST risk.

Observation:

  • A case of ST occurred despite the use of an EES.
  • The patient presented with factors contributing to increased ST risk.
  • Limited coronary flow and resistance to antiplatelet agents were identified as key issues.

Findings:

  • The combination of limited coronary flow and antiplatelet resistance significantly elevates ST risk.
  • Even modern stents like EES are not entirely immune to ST under specific adverse conditions.
  • This case underscores the multifactorial nature of stent thrombosis.

Implications:

  • Clinicians must consider combined risk factors for ST, including flow limitations and drug resistance.
  • Further research may be needed to optimize antiplatelet strategies in high-risk PCI patients.
  • Understanding these factors is crucial for improving long-term outcomes after stenting.